分子衍生恶性风险与阳性呼叫率作为个体细胞病理医师的不确定甲状腺细胞学诊断质量指标
本研究评估个体细胞病理医师对不确定甲状腺细胞学诊断的分子衍生恶性风险(MDROM)和阳性呼叫率(PCR)作为质量指标。回顾2年诊断及ThyroSeq v3结果,随访至少3年,比较MDROM和PCR与参考恶性风险及细胞学-组织学相关性。
要点
- MDROM和PCR可用于个体细胞病理医师的质量反馈。
- 细胞学-组织学相关中假阴性率10.9%,无假阳性。
核心结论
- MDROM和PCR可评估与参考恶性风险及彼此的一致性,并提供个体化反馈以促进质量改进。
研究设计与样本
- 回顾性研究,纳入2年期间个体细胞病理医师的甲状腺细胞学诊断和ThyroSeq v3结果,对AUS、FN和ONC诊断随访至少3年。
主要发现
- AUS、FN和ONC的总体MDROM分别为13.4%(范围5.8%-20.8%)、28.1%(范围22.1%-36.7%)和27.0%(范围19.5%-41.5%)。
- 多数个体医师的MDROM在参考恶性风险范围内。
- 细胞学-组织学相关中,55例切除病例有6例(10.9%)假阴性,无假阳性病例。
临床怎么用
- 可将MDROM和PCR作为个体细胞病理医师的质量指标,提供反馈以改进诊断一致性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Indeterminate thyroid cytopathology diagnoses represent differing degrees of risk that are corroborated by follow-up studies. However, traditional cytologic-histologic correlation may overestimate the risk of malignancy (ROM) because only a subset of cases undergo resection. Alternatively, some molecular tests provide probability of malignancy data to calculate the molecular-derived risk of malignancy (MDROM) and the positive call rate (PCR). The authors investigated MDROMs and PCRs of indeterminate diagnoses for individual cytopathologists as quality metrics. METHODS: This study was approved by the Department of Pathology Quality Improvement Program. Thyroid cytopathology diagnoses and ThyroSeq v3 results were retrieved for each cytopathologist for a 2-year period with at least 3 years of follow-up for the atypia of undetermined significance (AUS), follicular neoplasia (FN), and follicular neoplasia, oncocytic-type (ONC) cytopathologic diagnoses. MDROMs and PCRs were compared with reference ROMs and cytologic-histologic correlation outcomes. RESULTS: The overall MDROMs (and ranges for cytopathologists) for the AUS, FN, and ONC categories were 13.4% (range, 5.8%-20.8%), 28.1% (range, 22.1%-36.7%), and 27.0% (range, 19.5%-41.5%), respectively, and most individual cytopathologists' MDROMs were within reference ROM ranges. However, PCRs more effectively parsed the differences in cytopathologists' ROM performance. Although the overall PCRs were not significantly different across cytopathologists (p = .06), the AUS PCRs were quite different (p = .002). By cytologic-histologic correlation, six of 55 resected cases (10.9%) were falsely negative, and there were no false-positive cases. CONCLUSIONS: MDROMs and PCRs evaluate concordance with reference ROMs and with one another and provide individual feedback, which potentially facilitates quality improvement.
引用
- Ohori NP, Cuda JM, Bastacky SI, et al. Molecular-derived risk of malignancy and the related positive call rate of indeterminate thyroid cytology diagnoses as quality metrics for individual cytopathologists. Cancer Cytopathol. 2023. PMID: 37849056. doi:10.1002/cncy.22772
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。